Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.

Med Sci Monit · 2019 · PMC6909918 · PMID 31790382

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The findings showed that fruquintinib showed no significant difference on OS compared with regorafenib, and there was a trend for superiority in PFS of fruquintinib compared with regorafenib, which did not reach statistical significance [ 9 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.